Novartis | NOVN - Выручка от реализации

Биржевая цена
122.18
Изменение за день
1.00 0.83%
Ежемесячно
0.15%
Ежегодный
44.23%
Q2 прогноз
120.10




Продажи Изменить Дата
AbbVie USD 16.62B 840M 2025-12
Alcon AG USD 2.7B 110M 2025-12
Almirall EUR 547.63M 12.83M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Autolus Therapeutics Ltd USD 24.29M 1.68M 2025-12
Bayer EUR 11.44B 1.78B 2025-12
Biogen USD 2.28B 250M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Fresenius EUR 5.88B 400M 2025-12
Fresenius Medical Care EUR 5.07B 180M 2025-12
Galapagos EUR 900.82M 835.52M 2025-12
Genmab DKK 1.06B 36M 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
GRIFOLS EUR 1.98B 110M 2025-12
Hikma Pharmaceutical USD 1.69B 863M 2025-12
J&J USD 24.6B 610M 2025-12
Lonza CHF 3.58B 63M 2025-06
Merck EUR 5.25B 70M 2025-12
Merck USD 16.4B 880M 2025-12
Novartis USD 13.86B 50M 2025-12
Novartis USD 13.86B 498M 2025-12
Novo Nordisk DKK 79.14B 4.16B 2025-12
Orion EUR 695.3M 272.1M 2025-12
Pfizer USD 17.58B 880M 2025-12
Philips EUR 5.1B 797M 2025-12
Recordati EUR 662M 37.65M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.3B 1.13B 2025-12
UCB EUR 4.25B 764M 2025-12